Back to results
US 2006/0034819 A1Published application
Proteins and methods useful for assessing risk of cardiovascular disease
AssigneeUnither Pharma, Inc.
InventorsRobert Balint, John Cooke
Life of this patent
Estimating the term…
Abstract
The invention relates to a mutant protein comprising at least a fragment of a mutant dimethylarginine dimethylaminohydrolase (DDAH) enzyme, wherein the fragment possesses an affinity for asymmetric N,N-dimethyl arginine (ADMA) and/or L,N-monomethylarginine (LNMMA), which exists at lower plasma levels than ADMA, and is deficient in hydrolyzing ADMA or LNMMA to citrulline, releasing citrulline, or both.
Claims16
1-26. (canceled)
A method for developing an asymmetric N,N-dymethyl arginine (ADMA) assay, the method comprising
- deriving from a wild type dimethylarginine dimethylaminohydolase (DDAH) enzyme a mutant library;
- selecting from the mutant library a DDAH mutant, wherein said mutant possesses an affinity for ADMA and has an affinity for arginine and symmetric dimethylarginine (SDMA) lower than the wild type DDAH enzyme.
Dependencies are inferred from the claim text.